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Purpose: In vivo, the coagulation pathway is triggered by formation of a high-affinity 
complex between the tissue factor of the injured vascular wall and the activated form of 
blood coagulation factor VI I  (VIIa). We used a rabbit model of arterial thrombosis to 
examine the antithrombotic effect of topically administered active site--inactivated recom- 
binant human factor VIIa (VIIai), which binds to tissue factor but is unable to initiate 
coagulation. 
Methods: Segments of both central arteries of rabbits' ears were isolated between vascular 
clamps, followed by arteriotomies and deep-vessel wall trauma. In each rabbit, the 
injured vessel segments were superfused with either ViIai (0.5 mg in 200 ~I vehide) or 
vehicle alone in a blinded random manner (n = 20). The vessels were then dosed with 
running sutures and reperfused. The effect of intravenously infused ViIai (4 mg/kg) or 
vehicle was studied in a separate series. 
Results: The administration of VIIai increased patency rates from 40% and 30% in the 
vehicle group at 30 and 120 minutes after reperfusion, respectively, to 85% and 75% in 
the VIIai group (p = 0.008 and p = 0.004). No antihemostatic side effects occurred: 
median arteriotomy bleeding times were 2 minutes in the vehicle group and lg2 minutes 
in the VIIai group (p = 1). By contrast, intravenous infusion of ViIai produced no 
antithrombotic effect. 
Conclusions: We have shown that topical administration of VIIai at arterial trauma sites 
produces an antithrombotic effect without he expense of a hemostatic defect. This mode 
of treatment seems to be highly attractive in the prevention of thrombotic omplications 
in surgery on blood vessels. (J Vasc Surg 1997;25:341-6.) 
In context with vascular surgery, antithrombotic 
intervention is frequcntly used to prevent hrombo- 
sis. However, systemic anticoagulation is associated 
with a number of undesirable side effects, mainly 
antihemostatic effects. Therefore, a logical approach 
to prevent hrombosis in vascular surgery would be 
the use of agents that bind to and are operative only 
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at the site of vascular epair and thus can be delivered 
topically. 
Blood coagulation is initiated when tissue factor, 
expressed after injury to the vessel wall, is exposed to 
coagulation factors V I I /V I Ia  in the bloodstream3 
Once expressed, tissue factor binds factor VI Ia with 
high affinity, and the assembly of the tissue factor- 
factor VI Ia complex results in markedly enhanced 
proteolytic activation of the substrates factor IX and 
factor X, resulting ultimately in thrombin genera- 
tion. Thrombin then converts fibrinogen into an 
adhesive fibrin matrix and elicits diverse cellular re- 
sponses through the signaling thrombin receptor. 
I f  we recognize the extrinsic pathway s the dom- 
inant coagulation pathway in vivo, thrombus forma- 
tion might therefore be blocked by saturation of 
exposed tissue factor with a modified factor VI Ia 
whose binding ability to tissue factor is preserved but 
whose enzymatic site has been inactivated. In this 
article, we test this hypothesis by use of an estab- 
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lished model of microarterial thrombosis in rab- 
bits .2-5 
METHODS 
Trauma model. Swedish loop rabbits of either 
sex were fed a standard pellet diet and given water ad 
libitum. They were observed to be free of disease at 
the laboratory for at least 1 week before use. All 
procedures were approved by the Ethics Committee 
of Animal Welfare in accordance with Swedish guide- 
lines. 
A cannula was inserted in a marginal ear vein of 
each rabbit, and anaesthesia was induced with 18 
mg/kg sodium pentobarbital nd maintained by re- 
peated injections. A cannula was placed in the aorta 
of each rabbit hrough one of the femorals for subse- 
quent use in blood sampling (intravenous series). 
Skin flaps were raised on both ears, and seg- 
ments of the central arteries 3 cm in length (outer 
diameter -1  mm) were prepared. All branches 
were ligated with 10-0 sutures and cut. The oper- 
ative field was superfused with isotonic saline solu- 
tion and covered with thin plastic films. To keep 
blood flow high and constant and to counteract 
vasospasm, the animals were placed on heat pads 
and kept slightly hyperthermic ata body tempera- 
ture of -39 .5°C  (normal body temperature, 
-38.5 ° C), and three drops of 10 mg/ml lido- 
caine were applied topically to the vessels after they 
were manipulated (after eperfusion and after test- 
ing patency at 30 minutes after reperfusion). 
Ve*sels on both sides were simultaneously placed 
in double microvascular clamps (S&T 2V, S&T Mar- 
keting Ltd., Neuhausen, Switzerland), thereby iso- 
lating 7 mm artery segments between the clamps. 
Longitudinal rteriotomies (7 mm) were performed, 
whereafter the clamps were approximated, the vessels 
repositioned, and the vascular lumina everted and 
flattened. Segments of 5 mm of vascular lumina were 
denuded with a scalpel blade No. 15 (Swann-Mor- 
ton, Sheffield, U.K.), thereby exposing deep layers of 
the tunica media. 6 The arteriotomies were closed 
with continuous 10-0 monofilament ylon sutures 
(Ethilon I0-0 BV-75-3, Ethicon Ltd, Edinburgh , 
U.K.). All surgical procedures were performed by 
one surgeon with use of a high-quality operating 
microscope (Wild M-650, Leica-Heerbrugg, Heer- 
brugg, Switzerland). 
Vessels were simultaneously reperfused by open- 
ing the vascular clamps. They were quicldy covered 
by saline-soaked gauze pads and inspected once a 
minute. The time until complete cessation of arteri- 
otomy bleeding was recorded. 
At 30 and I20 minutes after reperfusion, vessel 
patcncy was assessed with use of a standard microsur- 
gical empty-refill test7: The vessels were gently oc- 
cluded distal to the trauma rea with a pair of micro- 
forceps and emptied downstream with another pair 
of forceps. After release of the first pair of forceps, 
vessel refilling was assessed and vessels classed as 
patent (refilling) or occluded (no refilling). After the 
final patency test, vessels were excised and opened 
longitudinally, whereafter the thrombotic material 
was removed and weighed. 
Preparation of active site-inactivated factor 
VIIa (VIIai). Recombinant human factor VIIa 
was purified from culture media of a transfected 
baby hamster kidney cell line as described previ- 
ously. 8 The recombinant factor VIIa was inacti- 
vated by the addition of two molar excess of Phe- 
Phe-Arg chloromethylketone (FFRcmk, Bachem), 
whereafter the solution was incubated for 1 hour 
at 4 ° C. Surplus of FFRcmk was separated from 
FFRcmk-factor VIIa (VIIai) by ion-exchange 
chromatography. The VIIai solution was adjusted 
to a protein concentration of approximately 2 
mg/ml in 10 mmol/L  glycylglycine, 150 mmol/L  
sodium chloride and 10 mmol calcium chloride, 
pH 7.4, whereafter the solution was sterile-filtered 
and stored in aliquots at -80 ° C. 
Experimental protocol. Twenty rabbits (40 
vessels) were treated as follows in a blinded random 
fashion, with pairwise observations made in each 
animal: After the deep arterial trauma was per- 
formed, the exposed injury site on one ear was super- 
fused for 5 minutes with VIIa solution (a total of 0.5 
mg in 200 Ixl of vehicle) and on the other ear with 
vehicle (glycylglycine buffer). The superfused trauma 
fields were allowed to incubate with the solutions 
during an additional 5-minute period, whereafter all 
surplus olution was flushed away with isotonic saline 
solution. The arteriotomies were then closed and the 
vessels reperfused. For comparison, two groups of 
five rabbits each were treated by the intravenous 
route. Five rabbits (10 vessels) received 4 mg/kg of 
VIIai (2.1 mg/ml), given as a bolus injection 5 
minutes before vascular reperfusion, whereas five 
rabbits (10 vessels) received an equal volume of vehi- 
cle. 
Analysis of VIIai antigen. The concentration 
of VIIai in rabbit plasma was measured by enzyme- 
linked immunosorbent assay with use of the factor 
VII enzyme immunoassay ldtfrom Dab,  Denmark. 
Coagulation analyses. Blood (1.8 ml) was 
drawn from the aortic cannulas into plastic syringes 
that contained 0.2 ml of 3.85% sodium citrate just 
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before injection and at 5, 35, and 120 minutes after 
injection of substances. The postinjecrion time 
points corresponded to the release of the vascular 
clamps and the first and the second patency test, 
respectively. The samples were centrifuged at 5000 
rpm for 15 minutes; the plasma was then removed 
and frozen at -70  ° C. The prothrombin rime was 
analyzed with use of reagents from Organon. 
Statistical methods. Patency results were com- 
pared with the sign test, and thrombus weights and 
arteriotomy bleeding data were compared with the 
Mann-Whitney test, computed on StatXact soft- 
ware (CYTEL Software Corporation, Cambridge, 
Mass.). Two-sided p values are presented; p values 
<0.05 were considered to be statistically signifi- 
cant. 
RESULTS 
The topical administration of VIIai produced a
pronounced antithromboric effect as measured by 
vessel patency rates. In the VIIai group, the vessel 
patency was 85% at 30 minutes and 75% at 120 
minutes after reperfusion. Corresponding values in 
the vehicle group were 40% and 30%, respectively. 
The difference was statistically significant (p = 
0.008 and p = 0.004, respectively; Fig. 1, A). 
Median thrombus weights were correspondingly 
lower in the VIIai group (0.3 mg in the VIIai 
group and 0.5 mg in the vehicle group). However, 
the difference was not statistically significant (p = 
0.19). The range ofthrombus weights was wide in 
both the vehicle and the VIIai groups, and one 
outlier was found in the treatment group (Fig. 2). 
Median arteriotomy bleeding times were 11/2 min- 
utes in the VIIai group and 2 minutes in the 
vehicle group. The groups were statistically indis- 
tinguishable (p = 1). 
After intravenous bolus injection, the plasma lev- 
els of circulating VIIai antigen were markedly ele- 
vated and were sustained over time. Five minutes 
after injection, VIIai antigen concentration was 98 
txg/ml (median value). At 35 and 120 minutes after 
infusion, corresponding values were 68 and 45 
txg/ml. Correspondingly, the median prothrom- 
bin time was durably prolonged to around 1.5 
times the baseline throughout the observation in-
terval. However, in contrast o topical administra- 
tion, the intravenous administration of VIIai did 
not produce any antithrombotic effect; vessel pa- 
tency rates were almost identical in both the VIIai 
and the vehicle groups (Fig. 1, B). No antihemo- 
static side effects were noted in the intravenous 
series. 
DISCUSSION 
In this study we have, for the first time, demon- 
strated apronounced antithrombotic effect by block- 
ing tissue factor at sites of arterial trauma with topi- 
cally administered active site-inactivated factor VIIa, 
lending a direct in vivo support o the notion that 
tissue factor and the extrinsic pathway plays a major 
role in the initiation of blood coagulation. The find- 
ings agree with recent data from our group that 
showed antithrombotic effects of locally applied 
VIIai in a venous model. 9The antithrombotic effects 
observed in the present study are clearly superior to 
those obtained with a bolus of 1 mg (160 IU) /kg 
bodyweight of standard heparin in this model. 5
Moreover, the observed antithrombotic effects were 
sustained over time and were not accompanied by an 
antihemostatic effect. Interestingly, the absence of 
hemorrhagic side effects of human VIIai has also 
been noted by Harker et al., 1° with use of a well- 
characterized arterial model in baboons. 
Although pronounced as determined by patency 
rates, which is the main parameter of thrombus for- 
marion in this experimental setting, two findings of 
this study still indicate that the antithrombotic effect 
of the human VIIai in rabbits was incompletely ex- 
pressed. First, thrombus weights were not signifi- 
cantly reduced, although a clear trend toward a re- 
duction was observed, which differs from earlier data 
obtained with use of activated protein C and hirudin 
in this model, z-5 Second, intravenous administration 
of VIIai produced no antithrombotic effect, al- 
though the plasma levels of VIIai exceeded the phys- 
iologic factor VII levels at least 100-fold. The most 
obvious explanation is that the ability of human VIIai 
to bind to and interact with rabbit tissue factor is 
substantially reduced as a result of species pecificity 
(Janson et al.ll and our own data [not shown]). This 
hypothesis i strongly supported by the fact that a 
considerably ower intravenous dose of human VIIai 
produces adistinct anrithrombotic effect in aprimate 
model of thrombosis. H Human VIIai interacts 
poorly with rabbit tissue factor, and a 4 mg/kg dose 
does not seem to produce a concentration atsites of 
vascular injury sufficient to prevent thrombus forma- 
tion, which on the other hand is achieved by the very 
high local concentrations produced by topical ad- 
ministration. Thus it may be expected that human 
recombinant VIIai would have a profound anti- 
thrombotic effect when used topically (and possibly 
also systemically) in context with vascular interven- 
tions in humans. 
The findings clearly indicate a potential for 
VIIai as an antithrombotic therapy in context with 
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Fig. 1. A, When applied topically, VIIai produced apowerful antithrombotic effect, as mea- 
sured by vessel patency rates, that was evident both at 30 and 120 minutes after vascular 
reperfusion (  = 20 in both groups). B, When administered intravenously, a high dose of VIIai 
(4 mg/kg body weight) had no antithrombotic effect (n = 10 in both groups). 
a variety of vascular, cardiovascular, and recon- 
structive microvascular interventions. As a future 
prospect, VIIai may preferably be delivered 
through specially designed cannulas in context 
with balloon dilatation, for instance, in coronary 
angioplasty. Because VIIai inhibits the very start- 
ing point of  coagulation and may be delivered 
locally, undesirable systemic side effects would be 
practically precluded. Because VIIai is an endoge- 
nous protein, it would also lack the potential to 
produce allergic side effects. 
Our findings are compatible with those of Khouri 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 2 Arnljots, Ezban, and Hedner 345 
D3 
E 
1.5 -  
V 
o0 
03 
J m  
(I.) 
o0 
E 
0 
c'- 
I.- 
0 .5 -  
_ 
p=O. 19 
(33 
0 
0 
0 
G33:33:33 
03O 
0 
0 
0 
0 
0 
0033 ~ 
0 
(3:33 
0 
I 
003O O33333O 
Vehicle Vllai 
Fig. 2. After topical administration, the median thrombus weights were lower (although not 
statistically significant) i  the factor VIIai group than in the vehicle group. The individual 
observations are plotted (n = 20 in both groups), as well as different percentiles. Boxes include 
25th, 50th (thick lines), and 75th percentiles; bars show 10th and 90th percentiles. 
et al.,12 which showed an antithrombotic effect of 
topical administration of the endogenous inhibitor 
of the tissue factor/factor VIIa complex (tissue fac- 
tor pathway inhibitor [TFPI]). However, a principal 
difference is that factor VIIai blocks the very first 
activation step of blood coagulation and thus repre- 
sents the most direct mode of extrinsic pathway inhi- 
bition, whereas TFPI exerts its effect only after coag- 
ulation has been initiated because TFPI acts only in 
complex with coagulation factor Xa3 The risk of 
TFPI inducing an increased risk of bleeding may 
therefore be higher than if the tissue factor/factor 
VIIa complex formation is blocked at the site of 
injury, because the latter can be accomplished with- 
out influencing any of the circulating coagulation 
factors uch as factor X. 
An antithrombotic effect of topical vessel wash- 
out with heparin has been shown) 3 However, this 
effect is dependent on the presence of normal endo- 
thelium to which heparin can bind) 4 This approach 
is an indirect one because the stimulus for thrombus 
formation lies in the exposure ofdcep vascular layers. 
The effect of heparin would therefore reside in its 
capacity to localize its effect near but not in the 
trauma area. The effect of locally applied hcparin has 
been questioned much and seems to be ineffective in 
this model, is which is not surprising because locally 
applied heparin is not likely to produce antithrom- 
botic effects in vessels with large confluent areas of 
intimal denudation. 
In conclusion, topical administration of active 
site-inactivated factor VIIa at sites of arterial injury 
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produces  an ant i th rombot ic  effect, w i thout  the ex- 
pense o f  a hemostar ic  defect. This  mode o f  t reatment  
seems to be h ighly attractive in p revent ion  o f th rom-  
boric compl icat ions in surgery on  b lood  vessels and 
in context  wi th  noninvasive angioplasty. 
We gratefially thank associate professor Ul f  Str6mberg, 
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